

## Alessia Castellino, MD

*Curriculum vitae et studiorum*

July 4<sup>th</sup>, 2024

---

Languages spoken: Italian (mother language), English, French

### **Current position**

Hematology Physician, MD  
CAR-T cells Coordinator  
Hematology Department  
AO Santa Croce e Carle Hospital of Cuneo  
Via Michele Coppino, 12100 Cuneo, Italia  
Tel.:  
e-mail: [castellino.ale@ospedale.cuneo.it](mailto:castellino.ale@ospedale.cuneo.it) ,

### **Education**

From November 2021- ongoing PhD Program in Molecular Medicine, University of Torino, Torino, Italy

June 2021 II Level University Master "Diagnosi e terapia dei pazienti con linfoma e malattie linfoproliferative", University of Study of Udine and Trieste, Italy

Grade: II level; Title of Master Degree Thesis: Fertility preservation in lymphoma patients treated with immunochemotherapy regimens with or without radiotherapy: results of a retrospective multicenter Italian study (Ferty care). Supervisor of Master Degree Thesis: Prof. F. Zaja.

July 2018: Hematology specialization degree, University of Torino, with final score 70/70 cum laude Publication Dignity

From August 2013 to July 2018 Resident in Hematology, University of Torino, Torino, Italy

February 2013 Italian National Medical Board Exam (National License)

July 2012 M.D. degree, University of Torino, Italy, with a final score of 110/110 *cum laude* and Publication Dignity with a thesis entitled "New therapeutic strategies for elderly Diffuse Large B-cell Lymphoma patients: results of a phase I-II trial on the combination of immunomodulatory agents with standard chemoimmunotherapy".

2006 – 2012 Medical Student, University of Torino, Italy.

July 2006 Graduated from Scientific Lyceum with a final score of 100/100 *cum laude*.

### **PROFESSIONAL EXPERIENCE**

## Research

From December 2018: Research activity in Lymphoma Field at the Hematology Department of Hospital Santa Croce, Cuneo

November 2018: Award: Premio Minerva “What’s up: Giovani Talenti. Per la ricerca scientifica”

From October 2018: reviewer for “Cancer Management and Research” journal, for “Drug development and therapy management” journal, for “Expert Review in Hematology” and for “Oncology” journal

From August 2018: Research Collaborator for Mayo Clinic (Hematology Department, Lymphoma Unit)

June 2018: ASCO Merit Award, with a project on DLBCL in collaboration with FIL and Mayo Clinic

Jan 2018- July 2018 Lymphoma Research Fellow and Visiting Clinicians at Mayo Clinic, Rochester, MN, USA (Research focused on Lymphoma field)

2013 – July 2018 Hematology Fellow, Department of Hematology, University of Torino (Director: Dr U.Vitolo): reserch and clinical trial experiences on hematological malignancies, chemotherapy, biological therapies, biology and treatment of lymphoma and myeloproliferative disorders.

2009- 2012 Internal student at Hematology section, Department of Hematology, University of Torino (Director: Dr U.Vitolo): reserch and clinical trial experiences on hematological malignancies, chemotherapy, biological therapies, biology and treatment of lymphoma.

## Clinical

From December 2018: Physician in Hematology Department of Hospital Santa Croce, Cuneo (Dec 21st, 2018 – July 31<sup>st</sup>, 2019 as Collaborator, from Aug 1<sup>st</sup>, 2019 as internal physician)

01-30/11/18 Physician as general doctor and Hematology Consultant at Humanitas-Gradenigo Hospital, Torino

Jan 2018- July 2018 Lymphoma Research Fellow and Visiting Clinician at Mayo Clinic, Rochester, MN, USA (Lymphoma Unit + experience in CART unit)

2013- July 2018 Hematology Fellow, Department of Hematology, University of Torino (Director: Dr U.Vitolo): clinical activities focused on hematological malignancies, chemotherapy, biological therapies, biology and treatment of lymphoma and myeloproliferative disorders.

2009- 2012 Internal student at Hematology section, Department of Hematology, University of Torino (Director: Dr U.Vitolo): clinical fellowship on hematological malignancies, chemotherapy, biological therapies, biology and treatment of lymphoma.

**Scientific affiliations:** Member of Fondazione Italiana Linfomi (FIL)  
Member of the Italian Society of Hematology (SIE)

## Publications

### Full papers

1. G Menardi 1, **A Castellino** 2, C Castellino 2, M E Bersia 3, E Grande 3, G Fraternali 4, M Massaia 5, C Fruttero 6. Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report. J Med Case Rep. 2025 Jan 20;19(1):27. doi: 10.1186/s13256-024-04905-5.

2. Chauvie S, **Castellino A**, Bergesio F, De Maggi A, Durmo R Lymphoma: The Added Value of Radiomics, Volumes and Global Disease Assessment. *PET Clin.* 2024 Jun 22:S1556-8598(24)00055-5.
3. Annibali O, **Castellino A**, Cenfra N, et al. Fertility preservation in lymphoma patients treated with immunochemotherapy regimens with or without radiotherapy: results of a retrospective multicenter Italian study (Ferty care). *Leuk Lymphoma.* 2024 Jun 7:1-8.
4. Tavarozzi R, Zacchi G, Pietrasanta D, Catania G, **Castellino A**, Monaco F, Gandolfo C, Rivela P, Sofia A, Schiena N, Bertassello C, Limberti G, Zallio F, Zanni M, Ladetto. Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice. *M.Cancers (Basel).* 2023 Nov 13;15(22):5397.
5. Margiotta-Casaluci G, Bigliardi S, Cocito F, Meli E, Petrucci L, Nicolosi M, Annibali O, Boccomini C, Bozzoli V, **Castellino A**, Cattina F, Cenfra N, Ciavarella S, Kovalchuk S, Rotondo F, Fama A, Olivieri J, Zaja F. *Front Oncol.* Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi. 2023 Mar 10;13:1120967.
6. Caruso L, **Castellino A**, Dessì D, Flenghi L, Giordano A, Ibatici A, Massone C, Pileri A, Proietti I, Pupo L, Quaglino P, Rupoli S, Zinzani PL. Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas. *Cancer Manag Res.* 2022 Nov 22;14:3205-3221
7. **Alessia Castellino** 1 2, Yucai Wang 1, Melissa C Larson 3, Matthew J Maurer 3, Brian K Link 4, Umar Farooq 4, Andrew L Feldman 5, Sergei I Syrbu 6, Thomas M Habermann 1, Jonas Paludo 1, David J Inwards 1, Thomas E Witzig 1, Stephen M Ansell 1, Cristine Allmer 3, Susan L Slager 3, Jonathon B Cohen 7, Peter Martin 8, James R Cerhan 3, Grzegorz S Nowakowski. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. *Blood Adv.* 2022 Feb 22;6(4):1350-1360.
8. **Castellino A**, Santambrogio E, Rapezzi D, Massaia M. Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment. *Medicina (Kaunas).* 2021 Oct 14;57(10):1104. doi: 10.3390/medicina57101104.
9. **Alessia Castellino**1,\* Roberto Sorasio1, Fabrizio Giordano2, Andrea Bianchi3, Alessia Reali4, Stefano Giaccardi5, Claudia Castellino1, Elisa Santambrogio1, Ambra Buschiazzo3, Daniele Mattei1, Nicola Mordini1, Myriam Foglietta1, Ivana Celeghini1, Mariella Grasso1, Giulio Fraternali Orcioni2, Massimo Massaia1, Davide Rapezzi1. A Successful Case of Langerhans Cell Sarcoma Treated with a Combined Chemotherapy, Surgical and Radiotherapy Approach, Followed by Autologous Stem Cell Transplantation: A Case Report and Review of the Literature. *International journal of Clinical Studies & Medical Case Reports* ISSN 2692-5877 1 DOI: 10.46998/IJCMCR.2021.14.000344
10. **Alessia Castellino**1, Elena Migliore2, Chiara Brignone2, Mariella Grasso1, Remo Melchio2, Margherita Bonferroni1, Giobatta Cavallero2 1 Department of Hematology, AO Santa Croce e Carle, Cuneo, Italy; 2 Department of Internal Medicine, AO Santa Croce e Carle, Cuneo, Italy. Iron deficiency anemia and thrombosis in young women: a report of 9 cases *Ital J Gender-Specific Med* 2022; 8(1): online ahead of print. Received 29 December 2020; accepted 14 June 2021.
11. **Castellino A**, Tun AM, Wang Y, Habermann TM, King RL, Ristow KM, Cerhan JR, Inwards DJ, Paludo J, Ansell SM, Witzig TE, Nowakowski GS. Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. *Blood Cancer J.* 2021 Jan 7;11(1):8. doi: 10.1038/s41408-020-00394-z.
12. **Castellino A**, Elba S, Sorasio R, Castellino C, Bonferroni M, Grasso M, Grosso E, Giacchello R, Signorile AF, Celeghini I, Mattei D, Mordini N, Foglietta M, Masturzo B, Priotto R, Zonta A, Rapezzi D, Massaia M. Diagnosis of maternal Hodgkin lymphoma following abnormal findings at noninvasive prenatal screening test (NIPT): Report of two cases. *Clin Case Rep.* 2021 Jan 13;9(3):1066-1071. doi: 10.1002/ccr3.3593. eCollection 2021 Mar
13. Boddicker NJ, Larson MC, **Castellino A**, Herrmann J, Inwards DJ, Thanarajasingam G, Maurer MJ, Allmer C, Witzig TE, Nowakowski GS, Habermann TM, Villarraga HR, Slager SL, Cerhan JR, Thompson CA. Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. *Am J Hematol.* 2021 Aug 1;96(8):979-988. doi: 10.1002/ajh.26230. Epub 2021 May 27.
14. Bonello F, Grasso M, D'Agostino M, Celeghini I, **Castellino A**, Boccadoro M, Bringham S. The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. *Pharmaceuticals (Basel).* 2020 Dec 29;14(1):20. doi: 10.3390/ph14010020.
15. Elba S, **Castellino A**, Sorasio R, Castellino C, Bonferroni M, Mattei D, Strola G, Drandi D, Mordini N, Foglietta M, Rapezzi D, Celeghini I, Grasso M, Giordano F, Fraternali Orcioni G, Massaia M Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. *J Med Case Rep.* 2020 Jun 22;14(1):75. doi: 10.1186/s13256-020-02380-2.
16. Albano D, Laudicella R, Ferro P, Allocca M, Abenavoli E, Buschiazzo A, **Castellino A**, Chiaravalloti A, Cuccaro A, Cuppari L, Durmo R, Evangelista L, Frantellizzi V, Kovalchuk S, Linguanti F, Santo G, Bauckneht M, Annunziata S; Young Italian Association of Nuclear Medicine. The Role of 18F-FDG PET/CT

- in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study. *Cancers* (Basel). 2019 Nov 21;11(12):1831. doi: 10.3390/cancers11121831.
17. Santambrogio E, Nicolosi M, Vassallo F, **Castellino A**, Novo M, Chiappella A, Vitolo U. Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. *Expert Rev Hematol*. 2019 Sep;12(9):787-796. doi: 10.1080/17474086.2019.1643232. Epub 2019 Aug 8. PMID:31305170.
  18. Novo M, **Castellino A**, Nicolosi M, Santambrogio E, Vassallo F, Chiappella A, Vitolo U. High-grade B-cell lymphoma: how to diagnose and treat. *Expert Rev Hematol*. 2019 Jul;12(7):497-506. doi: 10.1080/17474086.2019.1624157. Epub 2019 Jun 19. PMID: 31150587.
  19. Marangon M, Stefoni V, **Castellino A**, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, Romano A, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL. Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. *Clin Lymphoma Myeloma Leuk*. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29. No abstract available. PMID:31080169
  20. **Alessia Castellino**1MD, Jose S. Pulido2MD, PhD, Patrick B. Johnston1MD, Kay M. Ristow1, N. Nora Bennani1MD, David J. Inwards1MD, William R. Macon3MD, Ivana NM Micallef1MD, Rebecca L. King3MD, Diva R. Salomao 3MD, Thomas E Witzig1MD, Thomas M. Habermann1MD, Grzegorz S. Nowakowski1MD. Role of Systemic High-Dose Methotrexate and combined approaches in the management of Vitreoretinal Lymphoma: a Single Center Experience 1990-2018. *Am J Hematol*. 2019 Mar;94(3):291-298. doi: 10.1002/ajh.25350. Epub 2018 Dec 5. PMID:30516868
  21. **Castellino A**, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. *Blood Cancer J*. 2018 Nov 8;8(11):108.
  22. Pulido JS, Johnston PB, Nowakowski GS, **Castellino A**, Raja H. The diagnosis and treatment of primary vitreoretinal lymphoma: a review. *Int J Retina Vitreous*. 2018 May 7;4:18.
  23. Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, Ansuinelli M, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, **Castellino A**, Califano C, Cavaliere M, Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL. Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). *Oncologist*. 2018 Apr 19.
  24. Ciochetto C, Botto B, Passera R, Bellò M, Benevolo G, Boccomini C, **Castellino A**, Chiappella A, Freilone R, Nicolosi M, Orsucci L, Pecoraro C, Pregno P, Bisi G, Vitolo U. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. *Ann Hematol*. 2018 Apr 16.
  25. Novo M, **Castellino A**, Chiappella A. Intensified therapy in diffuse large B-cell lymphoma. *Oncotarget*. 2017 Dec 29;9(16):12548-12549.
  26. **Castellino A**, Guidi S, Dellacasa CM, Gozzini A, Donnini I, Nozzoli C, Manetta S, Aydin S, Giaccone L, Festuccia M, Brunello L, Maffini E, Bruno B, David E, Busca A. Late-Onset Hepatic Venous Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide. *Mediterr J Hematol Infect Dis*. 2018 Jan 1;10(1):e2018.
  27. Ghione P, Cavallo F, Visco C, Chen Z, **Castellino A**, Tisi MC, Dogliotti I, Nicolosi M, Boccadoro M, Leonard JP, Vitolo U, Martin P. A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. *Br J Haematol*. 2017 Dec 19.
  28. Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, **Castellino A**, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. *Lancet Oncol*. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.
  29. A. Chiappella, E.Santambrogio, **A. Castellino**, M.Nicolosi and U.Vitolo. Integrating novel drugs to standard chemoimmunotherapy in DLBCL. *Expert Rev Hematol*. 2017 Aug;10(8):697-705.

30. Chiappella A, **Castellino A**, Nicolosi M, Santambrogio E, Vitolo U. Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. *Expert Rev Hematol*. 2017 Apr;10(4):289-297.
31. **Castellino A**, Santambrogio E, Nicolosi M, Botto B, Boccomini C, Vitolo U. Follicular Lymphoma: The Management of Elderly Patient. *Mediterr J Hematol Infect Dis*. 2017 Jan 1;9(1).
32. Chiappella A, **Castellino A**, Vitolo U. State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. *Hematol Oncol Clin North Am*. 2016 Dec;30(6):1147-1162.
33. Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, **Castellino A**, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G; Fondazione Italiana Linfomi. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. *Lancet Oncol*. 2014 Jun;15(7):730-7. doi: 10.1016/S1470-2045(14)70191-3. Epub 2014 May 13.
34. Chiappella A, Tucci A, **Castellino A**, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U; Fondazione Italiana Linfomi. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. *Haematologica*. 2013 Nov;98(11):1732-8. doi: 10.3324/haematol.2013.085134. Epub 2013 Jun 28.
35. **A. Castellino**, U. Vitolo. DLBCL in unusual locations. The management and treatment of primary testicular lymphoma. *Hematology Education: the education program for the annual congress of the European Hematology Association*. 2014; 8(1).

Date: July, 4<sup>th</sup> 2024

Signature: